Mark Bhatt

Mark Bhatt specializes in biomarker development for immunotherapy response prediction at Johns Hopkins, with expertise in tumor mutational burden and microsatellite instability. His research has contributed to the analytical and clinical validation of TMB as a predictive biomarker for checkpoint inhibitor therapy across tumor types. He evaluated the concordance between tissue and liquid biopsy TMB assessments and their clinical utility. His work advances the field of precision immunooncology by identifying which patients will benefit most from checkpoint inhibitors.